Molecular Cardioprotection: How Pediatric Myosin Inhibition Redefines the Economics of Congenital Heart Care
Dr. Dereck Mush, MD, MBA
Sophia Genetics
Standardizes clinical genomic data using AI to support precision oncology worldwide.
What they do
Sophia Genetics offers a cloud-based platform that analyzes genomic and clinical data. Hospitals, laboratories, and research institutions worldwide license this software to interpret complex genetic sequencing, facilitating more precise diagnoses and targeted treatment decisions for cancer and other rare genetic disorders.
The record
- Vertical
- Oncology
- Sub-segment
- Precision medicine platform
- Product type
- Platform software
- Stage
- Public
- Headquarters
- Saint-Sulpice, Switzerland
- Region
- Europe
- Founded
- 2011
- Total funding
- $250M raised
Notable investors: Generation Investment Management, Idinvest Partners, Balderton Capital, Alychlo.
Also in Oncology
Related on The Signal
Dr. Dereck Mush, MD, MBA
Beyond PD-L1: How the I3LUNG Consortium Validated Multimodal AI in 2,365 Advanced Lung Cancer Patients
Dr. Dereck Mush, MD, MBA
From Algae to Neural Circuits: What the 2026 Medicine Nobel Means for Optogenetics
Dr. Dereck Mush, MD, MBA
Overcoming the Solvent Front: How Jideytro Validates Nuvalent's Precision Oncology Playbook
Dr. Dereck Mush, MD, MBA